Sanofi

Latest stories

14h
Business Wire
AmpliPhi Biosciences Announces Appointment of Alexander Gaidamaka as Vice President of Chemistry, Manufacturing and ControlSAN DIEGO & RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY--(BUSINESS WIRE)--Ampl
AmpliPhi Biosciences Announces Appointment of Alexander Gaidamaka as Vice President of Chemistry, Manufacturing and Control
Business Wire / Posted 14 hours ago
SAN DIEGO & RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced... Read more
15h
Channel NewsAsia
Regeneron scientists discover key to excess bone growth in rare diseaseCHICAGO: Scientists at U.S. biotechnology company Regeneron Pharmaceuticals res
Regeneron scientists discover key to excess bone growth in rare disease
Channel NewsAsia / Posted 15 hours ago
CHICAGO: Scientists at U.S. biotechnology company Regeneron Pharmaceuticals researching a rare genetic disease that traps sufferers in a second skeleton have discovered a treatment that shuts down excessive bone growth in mice engineered to develop... Read more
3 related stories
19h
Londonist
A Journey Through The Dreams Of A Pharmaceutical BuildingDo buildings dream of electric sheep? In the case of Sanofi, a former pharmaceu
A Journey Through The Dreams Of A Pharmaceutical Building
Londonist / Posted 19 hours ago
Do buildings dream of electric sheep? In the case of Sanofi, a former pharmaceutical factory in Dagenham, dreams are made of a chorus of singing scientists line-dancing down an assembly line. Geraldine Pilgrim is known for productions that transform... Read more
1d
Business Wire
World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics - Market Opportunity and Forecasts Analysis for the $9 Billion MarketThe global CRPC market is expected to reach $9.5 billion by 2020, at a CAGR of
World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics - Market Opportunity and Forecasts Analysis for the $9 Billion Market
Business Wire / Posted yesterday
The global CRPC market is expected to reach $9.5 billion by 2020, at a CAGR of 9.1% during the forecast period (2015-2020) Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient... Read more
1d
News-Medical-Net
Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitorsArdelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focuse
Sanofi terminates option and license agreement for Ardelyx's portfolio of NaP2b inhibitors
News-Medical-Net / Posted yesterday
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Sanofi notified Ardelyx of its termination of the option and license agreement for Ardelyx's... Read more
1d
Computer Business Review
Google and Sanofi join forces to combat diabetesCompanies to work together on new digital technology and tools for diabetes. F
Google and Sanofi join forces to combat diabetes
Computer Business Review / Posted yesterday
Companies to work together on new digital technology and tools for diabetes. French pharmaceutical company Sanofi has teamed up with Google's life sciences team to improve care for people diagnosed with type 1 and type 2 diabetes. The companies... Read more
17 related stories
1d
Contra Costa Times Newspapers
Google making moves to disrupt diabetesMOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting the
Google making moves to disrupt diabetes
Contra Costa Times Newspapers / Posted yesterday
MOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting themselves with insulin, diabetics could one day use tiny gizmos to manage their disease -- testing blood sugar levels with an Internet-connected contact lens or a coin-size... Read more
17 related stories
1d
Contra Costa Times Newspapers
Google making moves to disrupt diabetesMOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting the
Google making moves to disrupt diabetes
Contra Costa Times Newspapers / Posted yesterday
MOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting themselves with insulin, diabetics could one day use tiny gizmos to manage their disease -- testing blood sugar levels with an Internet-connected contact lens or a coin-size... Read more
17 related stories
1d
The Daily Review
Google making moves to disrupt diabetesMOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting the
Google making moves to disrupt diabetes
The Daily Review / Posted yesterday
MOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting themselves with insulin, diabetics could one day use tiny gizmos to manage their disease -- testing blood sugar levels with an Internet-connected contact lens or a coin-size... Read more
17 related stories
1d
Bizjournals
Google, Sanofi team up to streamline diabetes care worldwideThe end game: reducing the risk of complications and ultimately lowering the co
Google, Sanofi team up to streamline diabetes care worldwide
Bizjournals / Posted yesterday
The end game: reducing the risk of complications and ultimately lowering the cost of managing type 1 and type 2 diabetes for nearly 30 million patients in the United States and nearly 400 million worldwide. The move comes as questions swirl about... Read more
17 related stories
1d
Channel NewsAsia
Sanofi, Regeneron say new cholesterol drug data positivePARIS: Sanofi and Regeneron Pharmaceuticals said on Tuesday that a study into t
Sanofi, Regeneron say new cholesterol drug data positive
Channel NewsAsia / Posted yesterday
PARIS: Sanofi and Regeneron Pharmaceuticals said on Tuesday that a study into their new cholesterol-lowering drug, Praluent, showed promising results. "In a new pooled analysis of heterozygous familial hypercholesterolaemia (HeFH) patients ...... Read more
2 related stories
1d
Channel NewsAsia
Europe gets Amgen cholesterol drug for 50-60 percent of US priceLONDON: Amgen is launching its injectable cholesterol drug in Europe at around
Europe gets Amgen cholesterol drug for 50-60 percent of US price
Channel NewsAsia / Posted yesterday
LONDON: Amgen is launching its injectable cholesterol drug in Europe at around half the U.S. price, in a move likely to stoke controversy about the way Americans end up paying far more than others for new medicines. Repatha belongs to a potent and... Read more
69 related stories
1d
MedCity News
Bristol-Myers Squibb will acquire immunotherapy group PromediorPRINCETON, NEW JERSEY, UNITED STATES – 2014/08/10: Bristol-Myers Squibb R&D hea
Bristol-Myers Squibb will acquire immunotherapy group Promedior
MedCity News / Posted yesterday
PRINCETON, NEW JERSEY, UNITED STATES – 2014/08/10: Bristol-Myers Squibb R&D headquarters. (Photo by John Greim/LightRocket via Getty Images) Bristol-Myers Squibb has paid for the right to acquire US clinical stage immunotherapy group Promedior in a... Read more
1d
Reuters UK Edition
Insulin infusion device maker CeQur raises $100 millionLONDON Privately held company CeQur, which is developing the world’s first thre
Insulin infusion device maker CeQur raises $100 million
Reuters UK Edition / Posted yesterday
LONDON Privately held company CeQur, which is developing the world’s first three-day insulin infusion device for people with type 2 diabetes, has raised $100 million in a funding round that shows strong investor appetite for hot medical... Read more
2d
Calcutta News
Sanofi collaborates with Google Life Science to improve diabetes care NEW YORK/ PARIS - Leading global healthcare leader Sanofi SA and the life sci
Sanofi collaborates with Google Life Science to improve diabetes care
Calcutta News / Posted 2 days ago
NEW YORK/ PARIS - Leading global healthcare leader Sanofi SA and the life sciences team at Google have decided to collaborate to improve care and outcomes for people with type 1... Read more
17 related stories
2d
iafrica.com
Google, Sanofi team up to treat diabetesGlobal healthcare company Sanofi and the life sciences team at Google announced
Google, Sanofi team up to treat diabetes
iafrica.com / Posted 2 days ago
Global healthcare company Sanofi and the life sciences team at Google announced on Monday that they are teaming up in an effort to improve care and outcomes for those with type 1 and 2 diabetes. The collaboration will see Sanofi apply its work in... Read more
2d
The Fremont Argus
Google making moves to disrupt diabetesMOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting the
Google making moves to disrupt diabetes
The Fremont Argus / Posted 2 days ago
MOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting themselves with insulin, diabetics could one day use tiny gizmos to manage their disease -- testing blood sugar levels with an Internet-connected contact lens or a coin-size... Read more
17 related stories
2d
The Mercury News
Google making moves to disrupt diabetesMOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting the
Google making moves to disrupt diabetes
The Mercury News / Posted 2 days ago
MOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting themselves with insulin, diabetics could one day use tiny gizmos to manage their disease -- testing blood sugar levels with an Internet-connected contact lens or a coin-size... Read more
17 related stories
2d
Silicon Valley
Google wants to disrupt diabetesMOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting the
Google wants to disrupt diabetes
Silicon Valley / Posted 2 days ago
MOUNTAIN VIEW -- Instead of pricking a finger before each meal or injecting themselves with insulin, diabetics could one day use tiny gizmos to manage their disease -- testing blood sugar levels with an Internet-connected contact lens or a coin-sized... Read more
17 related stories
2d
Computer World Australia
Google life sciences group to wage war on diabetesGoogle may still be working on a name for its recently spun off life sciences g
Google life sciences group to wage war on diabetes
Computer World Australia / Posted 2 days ago
Google may still be working on a name for its recently spun off life sciences group, but the division already has a foe: diabetes. On Monday, Google said the chronic disease will be the first illness the life sciences division focuses on as it... Read more
17 related stories
2d
The Fremont Argus
Silicon Valley tech stocks fall, but Twitter bucks trendToday: Twitter's stock jumps despite a rocky day for Wall Street. Also: Google
Silicon Valley tech stocks fall, but Twitter bucks trend
The Fremont Argus / Posted 2 days ago
Today: Twitter's stock jumps despite a rocky day for Wall Street. Also: Google's life sciences company ramps up efforts to disrupt diabetes. Apple teams up with Cisco in a move to sell more iPhones and iPads to business customers. The lead:... Read more
8 related stories
2d
Silicon Valley
Silicon Valley tech stocks fall, but Twitter bucks trendToday: Twitter's stock jumps despite a rocky day for Wall Street. Also: Google
Silicon Valley tech stocks fall, but Twitter bucks trend
Silicon Valley / Posted 2 days ago
Today: Twitter's stock jumps despite a rocky day for Wall Street. Also: Google's life sciences company ramps up efforts to disrupt diabetes. Apple teams up with Cisco in a move to sell more iPhones and iPads to business customers. The lead:... Read more
8 related stories
2d
PC Advisor
Google life sciences group to wage war on diabetesGoogle may still be working on a name for its recently spun off life sciences g
Google life sciences group to wage war on diabetes
PC Advisor / Posted 2 days ago
Google may still be working on a name for its recently spun off life sciences group, but the division already has a foe: diabetes. Google may still... Read more
17 related stories
2d
Engadget
Google Life Sciences is working on another diabetes-monitoring projectA few weeks ago, Google's Life Sciences division (which falls under Alphabet) a
Google Life Sciences is working on another diabetes-monitoring project
Engadget / Posted 2 days ago
A few weeks ago, Google's Life Sciences division (which falls under Alphabet) announced plans to work with Dexcom on a miniature glucose tracker. The division that handles Mountain View's health-minded efforts is also teaming up with Sanofi, a... Read more
17 related stories
2d
Market Watch
Google to work with Sanofi to fight diabetesGoogle Inc. said Monday its health-care-research unit agreed to work with Europ
Google to work with Sanofi to fight diabetes
Market Watch / Posted 2 days ago
Google Inc. said Monday its health-care-research unit agreed to work with European pharmaceutical major Sanofi SA on new ways to monitor and treat diabetes. The companies declined to say how much they are investing in the partnership. Sanofi is a... Read more
17 related stories
2d
The Huffington Post
Google Is Working On A Project To Help Improve Diabetes TreatmentAug. 31 -- Google Inc. and French drugmaker Sanofi SA said they will partner to
Google Is Working On A Project To Help Improve Diabetes Treatment
The Huffington Post / Posted 2 days ago
Aug. 31 -- Google Inc. and French drugmaker Sanofi SA said they will partner to develop tools to improve the management and treatment of diabetes. Sanofi will work with Google's life sciences team to collect, analyze and understand information... Read more
17 related stories
2d
FOX News
Google, Sanofi team up to improve diabetes careA person receives a test for diabetes during Care Harbor LA free medical clinic
Google, Sanofi team up to improve diabetes care
FOX News / Posted 2 days ago
A person receives a test for diabetes during Care Harbor LA free medical clinic in Los Angeles, California September 11, 2014. REUTERS/Mario Anzuoni Google Inc and French drugmaker Sanofi SA said they will partner to develop tools to improve the... Read more
17 related stories
2d
Channel NewsAsia
Google, Sanofi team up to improve diabetes careREUTERS - Google Inc and French drugmaker Sanofi SA said they will partner to d
Google, Sanofi team up to improve diabetes care
Channel NewsAsia / Posted 2 days ago
REUTERS - Google Inc and French drugmaker Sanofi SA said they will partner to develop tools to improve the management and treatment of diabetes. Sanofi will work with Google's life sciences team to collect, analyze and understand information... Read more
17 related stories
2d
Channel NewsAsia
Google, Sanofi team up to improve diabetes careREUTERS: Google Inc and French drugmaker Sanofi SA said they will partner to de
Google, Sanofi team up to improve diabetes care
Channel NewsAsia / Posted 2 days ago
REUTERS: Google Inc and French drugmaker Sanofi SA said they will partner to develop tools to improve the management and treatment of diabetes. Sanofi will work with Google's life sciences team to collect, analyze and understand information... Read more
17 related stories
2d
Reuters UK Edition
Google, Sanofi team up to improve diabetes careA woman walks past a logo of Google at the Global Mobile Internet Conference (G
Google, Sanofi team up to improve diabetes care
Reuters UK Edition / Posted 2 days ago
A woman walks past a logo of Google at the Global Mobile Internet Conference (GMIC) 2015 in Beijing, China, April 28, 2015. Sanofi will work with Google's life sciences team to collect, analyse and understand information impacting diabetes, which is... Read more
17 related stories
2d
Market Watch
Google, Sanofi join forces on Diabetes monitoring and treatmentGoogle Inc. said Monday its health-care-research unit agreed to work with Europ
Google, Sanofi join forces on Diabetes monitoring and treatment
Market Watch / Posted 2 days ago
Google Inc. said Monday its health-care-research unit agreed to work with European pharmaceutical major Sanofi SA on new ways to monitor and treat diabetes. The companies declined to say how much they are investing in the partnership. Sanofi SAN,... Read more
2d
Bizjournals
Trial suggests Alnylam drug may lower cholesterol with less-frequent injections than Amgen’sAlnylam has occupied its building at 300 Technology Square since 2003. Amgen’s
Trial suggests Alnylam drug may lower cholesterol with less-frequent injections than Amgen’s
Bizjournals / Posted 2 days ago
Alnylam has occupied its building at 300 Technology Square since 2003. Amgen’s newest cholesterol-lowering drug has only been approved for three days, with plans to launch this coming week. But already, Alnylam Pharmaceuticals in Cambridge is coming... Read more
69 related stories
3d
The New Age
US approves injectable anti-cholesterol drug RepathaUS regulators on Thursday approved Repatha, the second injectable drug of its k
US approves injectable anti-cholesterol drug Repatha
The New Age / Posted 3 days ago
US regulators on Thursday approved Repatha, the second injectable drug of its kind designed for certain patients with stubbornly high cholesterol which puts them at risk of heart disease. Repatha, also known as evolocumab, is made by Amgen and is... Read more
2 related stories
3d
Brisbane Times
Inspired by Warren Buffett, Perpetual's Garry Laurence is flying highBerkshire Hathaway chairman Warren Buffett's famous newsletters date back to th
Inspired by Warren Buffett, Perpetual's Garry Laurence is flying high
Brisbane Times / Posted 3 days ago
Berkshire Hathaway chairman Warren Buffett's famous newsletters date back to the 1970s. Photo: AP A lot of kids would have been happy to pick up the pocket money and think of something else to do with their life – but not Perpetual Investments... Read more
4 related stories
3d
WA Today
Inspired by Warren Buffett, Perpetual's Garry Laurence is flying highBerkshire Hathaway chairman Warren Buffett's famous newsletters date back to th
Inspired by Warren Buffett, Perpetual's Garry Laurence is flying high
WA Today / Posted 3 days ago
Berkshire Hathaway chairman Warren Buffett's famous newsletters date back to the 1970s. Photo: AP A lot of kids would have been happy to pick up the pocket money and think of something else to do with their life – but not Perpetual Investments... Read more
4 related stories
3d
The Age
Inspired by Warren Buffett, Perpetual's Garry Laurence is flying highBerkshire Hathaway chairman Warren Buffett's famous newsletters date back to th
Inspired by Warren Buffett, Perpetual's Garry Laurence is flying high
The Age / Posted 3 days ago
Berkshire Hathaway chairman Warren Buffett's famous newsletters date back to the 1970s. Photo: AP A lot of kids would have been happy to pick up the pocket money and think of something else to do with their life – but not Perpetual Investments... Read more
4 related stories
3d
Sydney Morning Herald
Inspired by Warren Buffett, Perpetual's Garry Laurence is flying highBerkshire Hathaway chairman Warren Buffett's famous newsletters date back to th
Inspired by Warren Buffett, Perpetual's Garry Laurence is flying high
Sydney Morning Herald / Posted 3 days ago
Berkshire Hathaway chairman Warren Buffett's famous newsletters date back to the 1970s. Photo: AP A lot of kids would have been happy to pick up the pocket money and think of something else to do with their life – but not Perpetual Investments... Read more
4 related stories
3d
Canberra Times
Inspired by Warren Buffett, Perpetual's Garry Laurence is flying highBerkshire Hathaway chairman Warren Buffett's famous newsletters date back to th
Inspired by Warren Buffett, Perpetual's Garry Laurence is flying high
Canberra Times / Posted 3 days ago
Berkshire Hathaway chairman Warren Buffett's famous newsletters date back to the 1970s. Photo: AP A lot of kids would have been happy to pick up the pocket money and think of something else to do with their life – but not Perpetual Investments... Read more
4 related stories
4d
Business Wire
ALN-PCSsc Achieves Quarterly and Potentially Bi-Annual Subcutaneous Dose Regimen Profile for Effective LDL-C Lowering in Phase 1 Clinical StudyIn the Phase 1 study, subcutaneous administration of ALN-PCSsc resulted in an u
ALN-PCSsc Achieves Quarterly and Potentially Bi-Annual Subcutaneous Dose Regimen Profile for Effective LDL-C Lowering in Phase 1 Clinical Study
Business Wire / Posted 4 days ago
In the Phase 1 study, subcutaneous administration of ALN-PCSsc resulted in an up to 83% lowering of LDL-C, with an up to 64 ± 5% mean maximum reduction, comparable to published results for anti-PCSK9 MAbs (Zhang XL., et al., BMC Med, 2015). Similar... Read more
69 related stories
4d
Channel NewsAsia
Alnylam, Medicines cholesterol drug lasts months after one shotLONDON: A new drug in early development cuts cholesterol as much as two potent
Alnylam, Medicines cholesterol drug lasts months after one shot
Channel NewsAsia / Posted 4 days ago
LONDON: A new drug in early development cuts cholesterol as much as two potent injections recently cleared for sale but lasts much longer, meaning it may need to be given only every three to six months, initial findings suggest. Results with Alnylam... Read more
69 related stories
4d
FOX40 Sacramento
FDA Approves Second In New Class Of Cholesterol Lowering Drugs(CNN) — The FDA approved the new cholesterol-lowering drug Repatha (evolocumab)
FDA Approves Second In New Class Of Cholesterol Lowering Drugs
FOX40 Sacramento / Posted 4 days ago
(CNN) — The FDA approved the new cholesterol-lowering drug Repatha (evolocumab) on Thursday. The injectable drug from Amgen is the second in a new class of drugs called PCSK9 inhibitors. It works by making the liver more efficient at getting rid of... Read more
69 related stories
4d
Channel NewsAsia
European heart experts okay longer use of blood thinnersLONDON: European heart experts on Saturday endorsed the potential use of multip
European heart experts okay longer use of blood thinners
Channel NewsAsia / Posted 4 days ago
LONDON: European heart experts on Saturday endorsed the potential use of multiple blood thinning drugs for heart attack patients beyond one year, in a move that may boost demand for AstraZeneca's Brilinta. New European Society of Cardiology (ESC)... Read more
5d
KEPR Pasco
Amgen wins approval for second biotech cholesterol drug WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine
Amgen wins approval for second biotech cholesterol drug
KEPR Pasco / Posted 5 days ago
WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that... Read more
69 related stories
5d
KBOI-TV Boise
Amgen wins approval for second biotech cholesterol drug WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine
Amgen wins approval for second biotech cholesterol drug
KBOI-TV Boise / Posted 5 days ago
WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that... Read more
69 related stories
5d
KIMA Yakima
Amgen wins approval for second biotech cholesterol drug WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine
Amgen wins approval for second biotech cholesterol drug
KIMA Yakima / Posted 5 days ago
WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that... Read more
69 related stories
5d
KVAL Eugene
Amgen wins approval for second biotech cholesterol drug WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine
Amgen wins approval for second biotech cholesterol drug
KVAL Eugene / Posted 5 days ago
WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that... Read more
69 related stories
5d
KOMO Seattle
Amgen wins approval for second biotech cholesterol drug WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine
Amgen wins approval for second biotech cholesterol drug
KOMO Seattle / Posted 5 days ago
WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that... Read more
69 related stories
5d
Bakersfield Now
Amgen wins approval for second biotech cholesterol drug WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine
Amgen wins approval for second biotech cholesterol drug
Bakersfield Now / Posted 5 days ago
WASHINGTON (AP) — Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that... Read more
69 related stories
5d
WDIO Duluth
Amgen Wins Approval for Second Biotech Cholesterol DrugUpdated: 08/28/2015 11:24 AM Created: 08/28/2015 11:19 AM WDIO.com By: MATTHE
Amgen Wins Approval for Second Biotech Cholesterol Drug
WDIO Duluth / Posted 5 days ago
Updated: 08/28/2015 11:24 AM Created: 08/28/2015 11:19 AM WDIO.com By: MATTHEW PERRONE AP Health Writer WASHINGTON (AP) - Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce... Read more
69 related stories
5d
Business Wire
Magellan Rx Management Offers Key Strategies to Manage PCSK9 TherapiesSCOTTSDALE, Ariz.--(BUSINESS WIRE)--Following the approval of evolocumab (Repat
Magellan Rx Management Offers Key Strategies to Manage PCSK9 Therapies
Business Wire / Posted 5 days ago
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Following the approval of evolocumab (Repatha™; Amgen) by the Food and Drug Administration (FDA) yesterday, Magellan Rx Management, the pharmacy benefit management division of Magellan Health, Inc. (NASDAQ: MGLN),... Read more
69 related stories
More

People in this news